• 1
    Brown MS, Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc Natl Acad Sci USA 1974; 71: 78892.
  • 2
    Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974; 49: 47688.
  • 3
    Nordestgaard BG, Chapman MJ, Humphries SE et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 347890.
  • 4
    Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97: 395664.
  • 5
    Civeira F. Hypercholesterolemia IPoMoF. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173: 5568.
  • 6
    Usifo E, Leigh SE, Whittall RA et al. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet 2012; 76: 387401.
  • 7
    Innerarity TL, Mahley RW, Weisgraber KH et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 1990; 31: 133749.
  • 8
    Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J Clin Invest 1998; 101: 108493.
  • 9
    Abifadel M, Varret M, Rabès JP et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 1546.
  • 10
    Harada-Shiba M, Takagi A, Miyamoto Y et al. Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab 2003; 88: 25417.
  • 11
    Versmissen J, Oosterveer DM, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337: a2423.
  • 12
    Sharma P, Boyers D, Boachie C et al. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation. Health Technol Assess 2012; 16: 1266.
  • 13
    Futema M, Plagnol V, Whittall RA, Neil HA, Humphries SE, Group SBR, UK10K.Use of targeted exome sequencing as a diagnostic tool for Familial Hypercholesterolaemia. J Med Genet 2012; 49: 6449.
  • 14
    Rios J, Stein E, Shendure J, Hobbs HH, Cohen JC. Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia. Hum Mol Genet 2010; 19: 43138.
  • 15
    Faiz F, Allcock RJ, Hooper AJ, van Bockxmeer FM. Detection of variations and identifying genomic breakpoints for large deletions in the LDLR by Ion Torrent semiconductor sequencing. Atherosclerosis 2013; 230: 24955.
  • 16
    Hinchcliffe M, Le H, Fimmel A et al. Diagnostic validation of a familial hypercholesterolaemia cohort provides a model for using targeted next generation DNA sequencing in the clinical setting. Pathology 2014; 46: 608.
  • 17
    Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423.
  • 18
    Johns MB, Paulus-Thomas JE. Purification of human genomic DNA from whole blood using sodium perchlorate in place of phenol. Anal Biochem 1989; 180: 2768.
  • 19
    Abifadel M, Bernier L, Dubuc G et al. A PCSK9 variant and familial combined hyperlipidaemia. J Med Genet 2008; 45: 7806.
  • 20
    Lind S, Rystedt E, Eriksson M, Wiklund O, Angelin B, Eggertsen G. Genetic characterization of Swedish patients with familial hypercholesterolemia: a heterogeneous pattern of mutations in the LDL receptor gene. Atherosclerosis 2002; 163: 399407.
  • 21
    Widhalm K, Dirisamer A, Lindemayr A, Kostner G. Diagnosis of families with familial hypercholesterolaemia and/or Apo B-100 defect by means of DNA analysis of LDL-receptor gene mutations. J Inherit Metab Dis 2007; 30: 23947.
  • 22
    Alves AC, Etxebarria A, Soutar AK, Martin C, Bourbon M. Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia. Hum Mol Genet 2014; 23: 181728.
  • 23
    Hollants S, Redeker EJ, Matthijs G. Microfluidic amplification as a tool for massive parallel sequencing of the familial hypercholesterolemia genes. Clin Chem 2012; 58: 71724.
  • 24
    Vandrovcova J, Thomas ER, Atanur SS et al. The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia. Genet Med 2013; 15: 94857.
  • 25
    Lind S, Eriksson M, Rystedt E, Wiklund O, Angelin B, Eggertsen G. Low frequency of the common Norwegian and Finnish LDL-receptor mutations in Swedish patients with familial hypercholesterolaemia. J Intern Med 1998; 244: 1925.
  • 26
    Goldstein DB, Allen A, Keebler J et al. Sequencing studies in human genetics: design and interpretation. Nat Rev Genet 2013; 14: 46070.